GTG Insider Trading

Insider Ownership Percentage: 10.33%
Insider Buying (Last 12 Months): A$80,237.17
Insider Selling (Last 12 Months): A$0.00

Genetic Technologies Insider Trading History Chart

This chart shows the insider buying and selling history at Genetic Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Genetic Technologies Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 01/1/2000 01:00 AM ET

This chart shows the closing price history over time for GTG up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Genetic Technologies Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2024Peter RubinsteinInsiderBuy617,209A$0.13A$80,237.17
12/21/2023Jerzy (George) MuchnickiInsiderExpiry57,500,000A$0.15A$8,625,000.00
1/30/2023Jerzy (George) MuchnickiInsiderSell38,400,000A$0.00A$38,400.00
11/9/2022Peter RubinsteinInsiderExpiry125,000,000A$0.00A$375,000.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Genetic Technologies (ASX:GTG)

Genetic Technologies logo
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
Read More on Genetic Technologies

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

8.62%

Beta

0.42

Who are the company insiders with the largest holdings of Genetic Technologies?

Genetic Technologies' top insider investors include:
  1. Jerzy (George) Muchnicki (Insider)
  2. Peter Rubinstein (Insider)
Learn More about top insider investors at Genetic Technologies.